Bleakley Financial Group LLC acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,041 shares of the specialty pharmaceutical company’s stock, valued at approximately $227,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Versant Capital Management Inc grew its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its stake in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $33,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Piper Sandler reduced their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Royal Bank of Canada raised their price target on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $205.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.43.
Jazz Pharmaceuticals Trading Down 1.7 %
Shares of Jazz Pharmaceuticals stock opened at $111.13 on Thursday. The firm has a market cap of $7.01 billion, a price-to-earnings ratio of 22.91, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.48. The company’s 50-day simple moving average is $111.05 and its 200-day simple moving average is $109.66. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. As a group, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.
Insiders Place Their Bets
In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.20% of the stock is currently owned by company insiders.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Featured Articles
- Five stocks we like better than Jazz Pharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Using the MarketBeat Dividend Tax Calculator
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.